NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-EGFR/c-Met bispecific antibody EMB-01
A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR; c-Mesenchymal-Epithelial Transition; cMet; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody EMB-01 simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In EMB-01, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-cMET/EGFR bispecific antibody EMB-01
anti-EGFR/anti-c-Met bispecific antibody EMB-01
bispecific antibody EMB-01
FIT-013a
Code name:EMB 01
EMB01
EMB-01